Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of targeted agents

Oncologist

Volumn 11, Issue 2, 2006, Pages 152-164

  Reardon, David A ^a   Wen, Patrick Y ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis inhibitors; Glioblastoma multiforme; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; AP 23573; ATRASENTAN; BATIMASTAT; BEVACIZUMAB; BORTEZOMIB; CARMUSTINE; CELECOXIB; CILENGITIDE; CP 673451; CP 676451; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; LENALIDOMIDE; LOMUSTINE; LONAFARNIB; METALLOPROTEINASE INHIBITOR; PACLITAXEL; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ROFECOXIB; SEMAXANIB; SI 27; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ANTIANGIOGENIC ACTIVITY; ASTROCYTOMA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; GENE TARGETING; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; IMMUNOTHERAPY; INTESTINE PERFORATION; LUNG EDEMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RHINITIS; THROMBOCYTOPENIA; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; FARNESYLTRANSTRANSFERASE; GLIOBLASTOMA; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 32944479646     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.11-2-152     Document Type: Review

References (104)

1. Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin Oncol 2003;30(suppl 19):4-9.
2. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004;31:635-644.
3. Uddin S, Jarmi T, Hariharan S. Glioblastoma multiforme. Available at http://www.emedicine.com/NEURO/topic147.htm. Accessed March 15, 2005.
4. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993;3:255-268.
5. DeAngelis LM. Chemotherapy for brain tumors - a new beginning. N Engl J Med 2005;352:1036-1038.
6. Sandberg-Wollheim M, Malmstrom P, Stromblad LG et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991;68:22-29.
7. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-1329.
8. Tysnes BB, Mahesparan R. Biological mechanisms of glioma invasion and potential therapeutic targets. J Neurooncol 2001;53:129-147.
9. Benjamin R, Capparella J, Brown A. Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J 2003;9:82-90.
10. Kesari S, Ramakrishna N, Sauvageot C et al. Targeted molecular therapy of malignant gliomas. Curr Neurol Neurosci Rep 2005;5:186-197.
11. Ohgaki H. Genetic pathways to glioblastomas. Neuropatholology 2005;25:1-7.
12. Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333-343.
13. Carpentier A. Neuro-oncology: The growing role of chemotherapy in glioma. Lancet Neurol 2005;4:4-5.
14. Fine HA, Dear KB, Loeffler JS et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-2597.
15. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002;359:1011-1018.
16. Sipos L, Vitanovics D, Afra D. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. Ideggyogy Sz 2004;57:394-399.
17. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
18. Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-3857.
19. Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-1874.
20. Jendrossek V, Belka C, Bamberg M. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin Investig Drugs 2003;12:1899-1924.
21. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96.
22. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-142.
23. Lieberman FS, Cloughesy T, Fine H et al. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J Clin Oncol 2004;22:1510.
24. Prados MD, Langorn KR, Chang S et al. Phase I study of erlotinib alone and combined with temozolomide in patients with stable or recurrent glioma. Neuro-Oncology 2005;8:67-78.
25. Vogelbaum MA, Peereboom D, Stevens G et al. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: Interim results. J Clin Oncol 2004;22:1558a.
26. Raizer JJ, Abrey LE, Wen P et al. A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. J Clin Oncol 2004;22:1502a.
27. Marie Y, Carpentier AF, Omuro AM et al. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005;64:1444-1445.
28. Haas-Kojan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-887.
29. Spector NL, Xia W, Burris H 3rd et al. Study of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-2512.
30. Traxler P, Allegrini PR, Brandt R et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64:4931-4941.
31. Wen PY, Yung W, Lamborn K et al. Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99-08). Poster presented at the Society for Neuro-Oncology 9th Annual Meeting, Toronto, Canada, November 18-21, 2004.
32. Raymond E, Brandes A, Van Oosterom A et al. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study. J Clin Oncol 2004;22:1501a.
33. Holdhoff M, Kreuzer KA, Appelt C et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005;34:181-185.
34. Roberts WG, Whalen PM, Soderstrome E et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673, 451. Cancer Res 2005;65:957-966.
35. Goldbrunner RH, Bendszus M, Wood J et al. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004;55:426-432.
36. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
37. Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-715.
38. Fine HA, Wen PY, Maher EA et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003;21:2299-2304.
39. Taga T, Suzuki A, Gonzalez-Gomez I et al. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002;98:690-697.
40. Keyes KA, Mann L, Sherman M et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53:133-140.
41. Prasad G, Wang H, Hill DL et al. Recent advances in experimental molecular therapeutics for malignant gliomas. Curr Med Chem Anti-Canc Agents 2004;4:347-361.
42. Nelson JB. Endothelin receptor antagonists. World J Urol 2005;23:19-27.
43. Tohnya TM, Ng SS, Dahut WL et al. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer 2004;2:241-243.
44. New P. Cyclooxygenase in the treatment of glioma: its complex role in signal transduction. Cancer Control 2004;11:152-164.
45. Barnett FH, Scharer-Schuksz M, Wood M et al. Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure. Gene Ther 2004;11:1283-1289.
46. Farhadi MR, Capelle HH, Erber R et al. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J Neurosurg 2005;102:363-370.
47. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
48. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neurooncol 2005;7:369.
49. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 2003;3:595-614.
50. Cloughesy TF, Kuhn J, Wen P et al. Two phase II trials of R115777 (Zarnestra®) in patients with recurrent glioblastoma multiforme: a comparison of patients on enzyme-inducing anti-epileptic drugs (EIAED) and not on EIAED at maximum tolerated dose respectively: a North American Brain Tumor Consortium (NABTC) Report. Neurooncol 2003;5:349.
51. Caponigro F, Casale M, Bryce J. Farnesyl transferase inhibitors in clinical development. Expert Opin Investig Drugs 2003;12:943-954.
52. Nakamura JL, Karlsson A, Arvold ND et al. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol 2005;71:215-222.
53. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 2004;4:105-128.
54. Mrugala MM, Kesari S, Ramakrishna N et al. Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther 2004;4:759-782.
55. Chang SM, Kuhn J, Wen P et al. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing anti-epileptic drugs. Invest New Drugs 2004;22:427-435.
56. Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23:357-361.
57. Tremont-Lukats IW, Gilbert MR. Advances in molecular therapies in patients with brain tumors. Cancer Control 2003;10:125-137.
58. Yin D, Zhou H, Kumagai T et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005;24:344-354.
59. Marks P, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
60. Chalmers A, Johnston P, Woodcock M et al. PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 2004;58:410-419.
61. Robe PA, Bentires-Alj M, Bonif M et al. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 2004;10:5595-5603.
62. Fujita M, Mizuno M, Nagasaka T et al. Aurora-B dysfunction of multinucleated giant cells in glioma detected by site-specific phosphorylated antibodies. J Neurosurg 2004;101:1012-1017.
63. Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol 2003;13:52-61.
64. Jungbluth AA, Stockert E, Huang HJ et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 2003;100:639-644.
65. 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 2004;58:972-975.
66. Lorimer IA, Keppler-Hafkemeyer A, Beers RA et al. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A 1996;93:14815-14820.
67. Cohen KA, Liu T, Bissonette R et al. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr Pharm Biotechnol 2003;4:39-49.
68. Menei P, Jadaud E, Faisant N et al. Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer 2004;100:405-410.
69. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003;65:3-13.
70. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003;88:105-111.
71. Kunwar S, Prados M, Chang S et al. Peritumoral convection-enhanced delivery of IL-13-PE38QQR in patients with recurrent malignant glioma - phase I interim results. Neurooncol 2003;5:350.
72. Sampson JH, Akabani G, Archer GE et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003;65:27-35.
73. Liu TF, Hall PD, Cohen KA et al. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 2005;11:329-334.
74. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 2004;3:737-745.
75. O'Reilly T, Wartmann M, Maira SM et al. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 2005;55:307-317.
76. Pipas JM, Meyer LP, Rhodes CH et al. A phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol 2005;71:301-305.
77. Reardon DA, Quinn JA, Rich JN et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005;104:1478-1486.
78. Goudar RK, Shi Q, Hjelmeland MD et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005;4:101-112.
79. Abdollahi A, Lipson KE, Sckell A et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003;63:8890-8898.
80. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 2004;58:927-931.
81. Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004;72:257-266.
82. Baumann F, Bjeljac M, Kollias SS et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004;67:191-200.
83. Dandekar DS, Lopez M, Carey RI et al. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 2005;115:484-492.
84. Reardon DA, Quinn JA, Vredenburgh J et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005;103:329-338.
85. Tuettenberg J, Grobholz R, Korn T et al. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 2005;131:31-40.
86. Fine HA, Kim L, Royce C et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 2005;23:1504a.
87. van den Bent M, Brandes A, Frenay M et al. Multicentre phase II study of imatinib mesylate (Glivec®) in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): an EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study. J Clin Oncol 2005;23:1501a.
88. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005;16:1702-1708.
89. Friedman HS, Quinn J, Rich J et al. Imatinib mesylate (Gleevec) plus hydroxyurea is an effective regimen in the treatment of recurrent malignant glioma. Phase 2 study results. J Clin Oncol 2005;23:1515a.
90. Sathornsumetee S, Reardon DA, Quinn J et al. Phase I dose escalation study of imatinib mesylate (Gleevec) plus standard-dosed temozolomide in the treatment of patients with malignant glioma. J Clin Oncol 2005;23:1540a.
91. Cloughesy T, Yung A, Vrendenberg J et al. Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. J Clin Oncol 2005;23:1507a.
92. Krishnan S, Brown P, Ballman K et al. Phase I trial of erlotinib with radiation therapy (RT) in patients with glioblastoma multiforme (GBM). J Clin Oncol 2005;23:1513a.
93. Brewer CJ, Suh JH, Stevens GH et al. Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly-diagnosed glioblastoma multiforme J Clin Oncol 2005;23:1567a.
94. Franceschi E, Lonardi S, Tosoni A et al. ZD1839 (Iressa) treatment for adult patients with progressive high-grade gliomas (HGG): an open label, single-arm, phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2005;23:1564a.
95. Rich JN, Reardon DA, Quinn JA et al. A phase I trial of gefitinib (Iressa; ZD1839) plus rapamycin for patients with recurrent malignant glioma. J Clin Oncol 2005;23:1565a.
96. Phuphanich S, Carson K, Grossman S et al. A phase I evaluation of the safety of escalating doses of atrasentan in adults with recurrent malignant glioma (MG). J Clin Oncol 2005;23:1526a.
97. Galanis E, Buckner JC, Maurer MJ et al. N997B: Phase II trial of CCI-779 in recurrent glioblastoma mutiforme (GBM): updated results and correlative laboratory analysis. J Clin Oncol 2005;23:1505a.
98. Prados M, Kunwar S, Lang FF et al. Final results of phase I/II studies of IL13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma. J Clin Oncol 2005;23:1506a.
99. Lassman AB. Molecular biology of gliomas. Curr Neurol Neurosci Rep 2004;4:228-233.
100. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med 2001;7:326-331.
101. Schrader B, Barth H, Lang EW et al. Spontaneous intracranial haematomas caused by neoplasms. Acta Neurochir (Wien) 2000;142:979-985.
102. Lawler SE, Peruzzi PP, Chiocca EA. Genetic strategies for brain tumor therapy. Cancer Gene Therapy 2005 (epub ahead of print).
103. Matsuno A, Nagashima T. Specific gene suppression using antisense strategy for growth suppression of glioma. Med Electron Microsc 2004;37:158-161.
104. Wheeler CJ, Black KL. Dendritic cell vaccines and obstacles to beneficial immunity in glioma patients. Curr Opin Mol Ther 2005;7:35-47.